Subtype
Anorectal Neoplasm
CI-CAN-00001814Explore in graph →
Non-malignant503 active trials1 approved drugs6 evidence items
- NCIt
- C215222
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001814Explore in graph →
Clinical trials
2,045 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06254521 | The Effects of Neoadjuvant Tislelizumab Combined With Chemotherapy in Locally Advanced MSS Rectal Cancer | recruiting | Phase 2 | 60 | First Affiliated Hospital of Guangxi Medical UniversityOTHER | 1 | Feb 12, 2024 | clinicaltrials |
| NCT05245474 | Neoadjuvant Long-course Chemoradiation Plus PD-1 Blockade for Mid-low Locally Advanced Rectal Cancer | recruiting | Phase 2 | 186 | Beijing Friendship HospitalOTHER | 1 | Jan 10, 2024 |
| NCT04889742 | Hyperthermia Enhanced Re-irradiation of Loco-regional Recurrent Tumors(HETERERO) | not yet recruiting | Phase 2 | 110 | Charite University, Berlin, GermanyOTHER | 1 | Dec 26, 2023 | clinicaltrials |
| NCT04894370 | Combination of Spartalizumab, mDCF and Radiotherapy in Patients With Metastatic Squamous Cell Anal Carcinoma(SPARTANA) | recruiting | Phase 2 | 34 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Dec 22, 2023 | clinicaltrials |
| NCT03840239 | TNT to Increase the Clinical Complete Response Rate for Distal LARC(TESS) | active not recruiting | Phase 2 | 98 | Sun Yat-sen UniversityOTHER | 1 | Oct 25, 2023 | clinicaltrials |
| NCT05450029 | Neoadjuvant Chemoradiotherapy Plus Sintilimab for Intermediate/High Immunoscore Locally Advanced Rectal Cancer(SILAR) | recruiting | Phase 2 | 51 | Yanhong DengOTHER | 1 | Sep 26, 2023 | clinicaltrials |
| NCT06014944 | Short-course Radiotherapy Combined With Furoquintinib and PD-1 Monoclonal Antibody(PMMR/MSS) | not yet recruiting | Phase 2 | 30 | Changhai HospitalOTHER | 0 | Aug 31, 2023 | clinicaltrials |
| NCT05998122 | Total Neoadjuvant Chemoradiotherapy Plus Anti-PD-1 in Subperitoneal Patients With Locally Advanced Rectal CancerPatients With Locally Advanced Rectal Cancer: A Prospective, Single Arm, Exploratory Study | not yet recruiting | Phase 2 | 45 | The First Hospital of Jilin UniversityOTHER | 1 | Aug 18, 2023 | clinicaltrials |
| NCT05969847 | Organ Preservation Following Enverolimab-based Total Neoadjuvant Therapy for Locally Advanced Very Low Rectal Cancer(TRACE-LE) | not yet recruiting | Phase 2 | 72 | 池畔OTHER | 1 | Aug 1, 2023 | clinicaltrials |
| NCT05939661 | A Multicenter Single-arm P2 to Evaluate Safety and Efficacy of the Total Neoadjuvant Therapy for cT2 Rectal Cancer(AMBITION) | recruiting | Phase 2 | 45 | Osaka UniversityOTHER | 1 | Jul 11, 2023 | clinicaltrials |
| NCT05807984 | Re-irradiation Therapy of Locally Recurrent Rectal Cancer With Carbon Ion | not yet recruiting | Phase 2 | 31 | Xin CaiOTHER | 1 | Apr 11, 2023 | clinicaltrials |
| NCT05794750 | Assess the Efficacy of Radiotherapy and Sequential Chemotherapy and AK104 Before TME Surgery for Local CRC（AK104-IIT-13）(AK104-IIT-13) | not yet recruiting | Phase 2 | 50 | JIN JINGOTHER | 0 | Apr 6, 2023 | clinicaltrials |
| NCT05136326 | Preoperative Chemoradiotherapy With CApecitabine and Temozolomide in MGMT Silenced, MSS, Locally Advanced RecTal Cancer(CATARTIC) | recruiting | Phase 2 | 21 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Mar 1, 2023 | clinicaltrials |
| NCT05359393 | A Combination Therapy Including Anti-PD-1 Immunotherapy in MSS Rectal Cancer With Resectable Distal Metastasis(Miracle-1) | not yet recruiting | Phase 2 | 52 | Fudan UniversityOTHER | 1 | Nov 14, 2022 | clinicaltrials |
| NCT05563922 | Organ Preservation Strategy of Total Neoadjuvant Chemoradiotherapy for Low Rectal Carcinoma(OP-TNT) | recruiting | Phase 2 | 56 | Shanghai Zhongshan HospitalOTHER | 1 | Oct 3, 2022 | clinicaltrials |
| NCT05484024 | Short-course Radiotherapy Followed by Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer | not yet recruiting | Phase 2 / Phase 3 | 588 | Chinese Academy of Medical SciencesOTHER | 1 | Aug 2, 2022 | clinicaltrials |
| NCT05300269 | SHR-1701 in Combination With Chemotherapy and Radiotherapy in Locally Advanced Rectal Cancer | recruiting | Phase 2 | 73 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Jul 29, 2022 | clinicaltrials |
| NCT04109755 | Neo-adjuvant Pembrolizumab and Radiotherapy in Localised MSS Rectal Cancer(PEMREC) | recruiting | Phase 2 | 25 | University Hospital, GenevaOTHER | 1 | Sep 30, 2021 | clinicaltrials |
| NCT05055635 | Pencil Beam Proton Therapy for Recurrences in Anal Cancer Patients Previously Treated With Radiotherapy (DACG 5)(ReRad III) | recruiting | Phase 2 | 55 | University of AarhusOTHER | 1 | Sep 24, 2021 | clinicaltrials |
| NCT04443543 | An Adaptive-design Prospective Cohort Study of Watch and Wait Strategy in Patients With Locally Advanced Rectal Cancer | not yet recruiting | Phase 2 | 222 | Fudan UniversityOTHER | 1 | Jun 30, 2020 | clinicaltrials |
| NCT03391843 | Neoadjuvant Chemotherapy Combined With Cetuximab for EGFR Wild Type Locally Advanced Rectal Cancer | active not recruiting | Phase 2 | 100 | RenJi HospitalOTHER | 1 | Jan 5, 2018 | clinicaltrials |
Data updated 23 days agoSource updated Feb 12, 2024source: clinicaltrials